Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 18/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.84 |
| ▸ | HTR1D | P28221 | 1/20 | 0.84 |
| ▸ | DRD3 | P35462 | 1/20 | 0.84 |
| ▸ | HTR2B | P41595 | 1/20 | 0.84 |
| ▸ | HTR5A | P47898 | 1/20 | 0.84 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14276543 | 1.00 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14528345 | 1.00 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL175710 | 0.92 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL5127692 | 0.92 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL29702219 | 0.92 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14528347 | 0.92 | NPY5R (1.00) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14276589 | 0.91 | NPY5R (0.83) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL5130637 | 0.91 | NPY5R (0.83) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL14408821 | 0.89 | NPY5R (0.81) | NPY5RADRB2CYP3A4HTR1AHTR1D | |
| SCHEMBL5382521 | 0.89 | NPY5R (0.81) | NPY5RADRB2CYP3A4HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1183245-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2007-05-09 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-6124331-A | TREATING ABNORMAL FEEDING DISORDERS (OBESITY AND BULIMIA NERVOSA), SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885ADRB2 124/4885CYP3A4 1350/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885ADRB2 124/4885CYP3A4 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.